Oxford Nanopore Technologies plc (LSE: ONT), the company delivering a new generation of nanopore-based molecular sensing, today announces the appointment of Sebastian Kronmueller as Chief Business Development Officer (CBDO), effective 4 January 2027. He will be based in the United States.
Sebastian will lead Oxford Nanopore's strategy and business development functions, including the development and implementation of key strategic initiatives and partnerships.
Sebastian joins from Philips, where he is Head of Strategy and Ventures, responsible for global strategy and key inorganic activities. Previously, he spent more than a decade at Siemens Healthineers in senior strategy, business development and operational leadership roles, most recently leading strategy and transformation for its global Diagnostics business.
Sebastian brings extensive experience across diagnostics, genomics and biopharma, including acquisitions, divestments, licensing agreements and strategic partnerships. He holds a Master's in Physics from the University of Munich and a Master's in Biomedical Informatics from Stanford University.
Francis Van Parys, Chief Executive Officer of Oxford Nanopore, commented: “Sebastian brings a rare combination of strategic insight and hands-on experience building businesses across diagnostics, genomics and healthcare. As Oxford Nanopore grows, we need to be increasingly deliberate about where we focus, where we partner and where we invest. Sebastian will play an important role in accelerating and executing on those decisions to further unlock our significant long-term growth opportunity.”
Sebastian Kronmueller added: “Oxford Nanopore has built a differentiated technology platform that creates great value for life sciences research, biopharma and clinical applications. What particularly attracted me is the opportunity to help turn that potential into further commercial growth and focused partnerships. I am delighted to join the team at such an important point in the Company's development.”
